Our test can detect all of the circulating variants. Aptitude routinely monitors emerging variants and variants of concern by conducting monthly in silico analyses using all available SARS-CoV-2 genetic sequences on the GISAID database. We align our primers with all known SARS-CoV-2 genetic sequences and look for 100% alignment between the primers and the target genes. The most recent analysis indicates an overall zero-mismatch rate of >99% for all analyzed SARS-CoV-2 sequences. We will continue to monitor emerging variants for significant mutations. Additionally, because of the way that our test is designed to detect mutations, we have not yet observed any variants or mutations that would negatively affect our test.
The FDA also regularly monitors SARS-CoV-2 mutations and their impact on COVID-19 tests. More information can be found here: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests.